Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Aspect Biosystems

Aspect Biosystems Ltd. is a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering. The company’s proprietary microfluidic 3D bioprinting technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. In addition to its internal programs, Aspect is focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to enable the creation of living, human tissues for medical research, therapeutic discovery, and regenerative medicine products.

  • Date:Tuesday, February 12
  • Time:9:30 AM - 9:45 AM
  • Room:Chelsea
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:23487
  • Goal for Presentation:Investment
  • Company Website:www.aspectbiosystems.com
  • Company HQ City:Vancouver
  • Company HQ State:British Columbia
  • Company HQ Country:Canada
  • Total Amount Raised to Date, in All Rounds:$10M+
  • Previous and Current Investors:Pangaea Ventures, Pallasite Ventures, Endure Capital, Relentless Pursuit Partners
  • CEO/Top Company Official:Tamer Mohamed
  • Year Founded:2013
  • Main Therapeutic Focus:Regenerative Medicine
  • Lead Product in Development:RX1 Bioprinter + portfolio of tissue products
  • Development Phase of Primary Product:Pre-Clinical
Speakers
Tamer Mohamed
Aspect Biosystems
Back